Compare BIVI & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIVI | PMI |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 14.1M |
| IPO Year | 2013 | N/A |
| Metric | BIVI | PMI |
|---|---|---|
| Price | $2.18 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 177.7K | ★ 6.3M |
| Earning Date | 05-11-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $0.11 |
| 52 Week High | $9.09 | $13.68 |
| Indicator | BIVI | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 37.92 |
| Support Level | $1.22 | $0.15 |
| Resistance Level | N/A | $0.27 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.36 | 18.51 |
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.